| P2093 | author name string | Bo Yu | |
| | Bing Su | |
| | Jianghong Wu | |
| | Xin Liao | |
| P2860 | cites work | Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia | Q37044749 |
| | Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells | Q37401245 |
| | Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition | Q39712667 |
| | Episodic Src activation in uveal melanoma revealed by kinase activity profiling. | Q39830805 |
| | Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells | Q39840354 |
| | Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro | Q40176252 |
| | Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells | Q40366043 |
| | The mechanism of cell cycle regulation by v-Src. | Q40775817 |
| | Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry | Q40976467 |
| | Microtubule integrity regulates src-like and extracellular signal-regulated kinase activities in human pro-monocytic cells. Importance for interleukin-1 production | Q41062029 |
| | Cytoskeleton reorganization induces the urokinase-type plasminogen activator gene via the Ras/extracellular signal-regulated kinase (ERK) signaling pathway | Q41133919 |
| | Membrane-microfilament interactions in ascites tumor cell microvilli. Identification and isolation of a large microfilament-associated membrane glycoprotein complex. | Q41158644 |
| | Integrin and cytoskeletal regulation of growth factor signaling to the MAP kinase pathway. | Q42819682 |
| | Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling. | Q43517848 |
| | Disassociation of MAPK activation and c-Fos expression in F9 embryonic carcinoma cells following retinoic acid-induced endoderm differentiation | Q43636975 |
| | Role of cell shape in growth control | Q44152787 |
| | pp60c‐src mediates ERK activation/nuclear localization and PAI‐1 gene expression in response to cellular deformation | Q44409581 |
| | Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. | Q45198729 |
| | Inhibition of Mek 1/2 kinase activity and stimulation of melanogenesis by 5,7-dimethoxycoumarin treatment of melanoma cells. | Q46020825 |
| | Regulation of p190 Rho-GAP by v-Src is linked to cytoskeletal disruption during transformation. | Q52533998 |
| | Association of the Ras to mitogen-activated protein kinase signal transduction pathway with microfilaments. Evidence for a p185(neu)-containing cell surface signal transduction particle linking the mitogenic pathway to a membrane-microfilament assoc | Q78177496 |
| | Newest findings on the oldest oncogene; how activated src does it | Q24313514 |
| | Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias | Q28246193 |
| | Actin polymerization is required for negative feedback regulation of epidermal growth factor-induced signal transduction | Q32019550 |
| | Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation | Q33394424 |
| | Mitf from neural crest to melanoma: signal transduction and transcription in the melanocyte lineage. | Q33970751 |
| | The tyrosine kinase inhibitor dasatinib induces a marked adipogenic differentiation of human multipotent mesenchymal stromal cells | Q34099289 |
| | Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias | Q34335004 |
| | Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. | Q34980474 |
| | A phase 2 trial of dasatinib in advanced melanoma | Q35048145 |
| | Role of MAP kinase in tumor progression and invasion | Q35186460 |
| | Targeted Inhibition of Src Kinase Signaling Attenuates Pancreatic Tumorigenesis | Q36253834 |
| | The Src signaling pathway: a potential target in melanoma and other malignancies | Q36675509 |
| | Chemotherapy for metastatic melanoma: time for a change? | Q36698282 |
| | Inhibition of Rho is required for cAMP-induced melanoma cell differentiation. | Q36873446 |
| | Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines | Q36940730 |
| P433 | issue | 2 | |
| P921 | main subject | dasatinib | Q419940 |
| | dasatinib monohydrate | Q27139135 |
| P304 | page(s) | 527-532 | |
| P577 | publication date | 2012-12-10 | |
| P1433 | published in | Oncology Letters | Q20640514 |
| P1476 | title | Dasatinib inhibits primary melanoma cell proliferation through morphology-dependent disruption of Src-ERK signaling | |
| P478 | volume | 5 | |